Project description:Whole exome sequencing of tumors and paired adjacent uninvolved tissues from 222 early stage NSCLC patients, in order to identify genomic drivers present in early-stage non-small cell lung cancer and determine the overall tumor mutational burden in early-stage non-small cell lung cancer.
Project description:Lung cancer is the worldwide leading cause of death from cancer. Tobacco usage is the major pathogenic factor, however, not all lung cancers can be attributable to smoking. The genetic aberrations that differ between smokers' and never-smokersM-bM-^@M-^Y lung carcinomas remain to a large extent unclear. We analyzed 72 early-stage primary lung carcinomas including small cell lung cancers, adenocarcinomas and squamous cell carcinomas by Illumina HT12 gene expression microarrays. Gene expression profiling of 72 lung carcinomas using Illumina HT-12 V3.0 microarrays.
Project description:To further understand the expression pattern of long non-coding RNAs in early stage lung squamous cell carcinoma (SCC), we have employed the Arraystar Human LncRNA Microarray V3.0 profiling as a discovery platform to identify lncRNAs which are differentially expressed in early stage lung SCC. Three pairs of tumor tissues and adjacent normal tissues of early stage lung SCC patients are used for microarray analysis.
Project description:Lung cancer is the worldwide leading cause of death from cancer. Tobacco usage is the major pathogenic factor, however, not all lung cancers can be attributable to smoking. The genetic aberrations that differ between smokers' and never-smokers’ lung carcinomas remain to a large extent unclear. We analyzed 72 early-stage primary lung carcinomas including small cell lung cancers LCNEC, adenocarcinomas and squamous cell carcinomas by Illumina HT12 gene expression microarrays.
Project description:Abstract from paper - Potti A, et al Keywords: Outcome, recurrence, adjuvant therapy, Early stage Non-small cell Lung Cancer, Lung Metgene Predictor
Project description:Validation of a histology-independent prognostic gene signature for early stage, non-small cell lung cancer including stage IA patients
